Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN
Regeneron Pharmaceuticals — Shareholder Meeting (June 2024)
28 slides from Regeneron Pharmaceuticals's shareholder meeting presentation, Jun 14, 2024
Slide 1: Meeting Agenda
Meeting Agenda 1. PROPOSALS 2. VOTING & VOTING RESULTS • Election of Directors • Ratification of Independent Registered Public Accounting Firm • Advisory Vote on Executive 3. COMPANY UPDATE Compensation (“Say-on-Pay” Vote) • Non-Binding Shareholder Proposal 4. QUESTIONS & ANSWERS
Slide 2: 2024 Annual Shareholder Meeting
2024 ANNUAL SHAREHOLDER M EETING J u n e 1 4 , 2 0 2 4
Slide 3: Note regarding forward-looking statements and non-GAAP financial measures
Note regarding forward-looking statements and non-GAAP financial measures This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual even
Slide 4: We remain committed to doing what's right
We remain committed to doing what’s right Following the science to improve treatment of disease Prioritizing investment in science & technology • Invent the technologies of tomorrow; pursue multiple • Continue industry-leading investment in R&D modalities and therapeutic areas o $4.4B in 2023, repre
Slide 5: Executing on our core competencies, investing in the future
Executing on our Investing in Looking ahead core competencies Regeneron to the future • Investing ~$5B into R&D • Over 35 therapeutic candidates in various stages of clinical development in 2024* #1 prescribed Now FDA approved • Pioneering novel therapeutic FDA approved anti- Aspire to become VEGF t
Slide 6: Key achievements from the past year
FDA approval of EYLEA HD – based on unprecedented durability data – with successful Key achievements launch positions retinal franchise for prolonged from the past year leadership position Regeneron to deliver long-term Exceptional Dupixent clinical and commercial shareholder value execution; unprec
Slide 7: Maintaining anti-VEGF category leadership with EYLEA HD launch
Maintaining anti-VEGF category leadership with EYLEA HD launch Building on 12+ years of safety and efficacy experience, breadth of indications, and flexible dosing regimens with unprecedented durability data 1Q 2024 combined U.S. revenues of $1.4 billion U.S. Net Product Sales, in $ Millions $43 $12
Slide 8: Dupixent: continued growth, continued opportunity
Continued growth, continued opportunity 1Q 2024 DUPIXENT global net sales grew 25%* to ~$3.1 billion Incremental market penetration, new indications, and younger populations represent significant opportunity for continued growth >850,000 patients on therapy globally +25%* Approved in FIVE indication
Slide 9: Delivering on "pipeline in a product" potential
Delivering on “pipeline in a product” potential Dupixent clinical trials have demonstrated that IL-4 and IL-13 are key drivers of multiple Type 2 allergic diseases Atopic Dermatitis Asthma Atopic Dermatitis CRSwNP Atopic Dermatitis Asthma Adults 18+ Adults/Adolescents 12+ Adolescent 12+ Adults 18+ P
Slide 10: Key growth driver and oncology portfolio foundation
Key growth driver and oncology portfolio foundation Market leader in advanced cutaneous squamous cell carcinoma and advanced basal cell carcinoma Strong and Consistent Growth • 1Q 2024 U.S. net product sales of $159M (+45% YoY) and rest of +44% world sales of $105M (+43%* YoY) Growth vs. 1Q23* Non-S
Slide 11: Expanding antibody and biologics leadership
Expanding antibody and biologics leadership Dupixent in COPD Dupixent + bispecific to reverse severe First biologic to achieve clinically meaningful allergy reduction in COPD exacerbations and First clinical trial for a potentially improvement in lung function groundbreaking approach for reversing *
Slide 12: Dupixent & itepekimab: two opportunities in COPD
DUPIXENT & itepekimab: Two opportunities to address high unmet need in COPD Itepekimab Type 2 Non-Type 2 (anti IL-33) • Potential to address COPD in (70% of COPD patients) Former Smokers • Potential to address COPD with a former smokers, regardless of Type 2 inflammatory phenotype DUPIXENT or Itepek
Slide 13: Novel treatment approach to combat severe allergy
Novel treatment approach to combat severe allergy: Linvoseltamab (BCMAxCD3) plus DUPIXENT (anti-IL4Rα) Transient plasma cell depletion with BCMAxCD3 Myeloma patients treated with plus sustained IL-4Rα blockade durably eliminates linvoseltamab rapidly reduce IgE levels1 IgE production in cynomolgus m
Slide 14: Harnessing the immune system to fight cancer
Harnessing the immune system to fight cancer By using our deep understanding of biology, genetics, and the immune system, Regeneron has validated 3 independent classes of internally-developed immuno-oncology agents in clinical trials Checkpoint Inhibitors CD3 Bispecifics CD28 Costimulatory Bispecifi
Slide 15: Combining two checkpoint inhibitors: fianlimab + cemiplimab
Combining two checkpoint inhibitors: fianlimab (anti-LAG-3) + cemiplimab (anti-PD-1) Results from three independent 1L metastatic melanoma cohorts from the FIH study demonstrated strong efficacy signal, including in patients treated with adjuvant anti-PD-1 therapy Phase 1 Phase 2 Phase 3 Results in
Slide 16: Regeneron's leading CD3 bispecifics
Regeneron’s Linvoseltamab (BCMAxCD3) – MM leading CD3 Linvoseltamab has the potential to be BLA accepted for Priority bispecifics the best-in-class BCMAxCD3 bispecific with its clinical profile, dosing, and Review in R/R MM (PDUFA August 22, 2024) administration EU submission accepted, Confirmatory
Slide 17: Progressing CD28 costimulatory bispecifics
Progressing CD28 costimulatory bispecifics Dose Proof-of- Dose Escalation Mechanism Expansion Status / Next Steps Combined with: Nezastomig Enrolling monotherapy cohort; (PSMAxCD28) combo with PSMAxCD3 to start 2H24 Cemiplimab PSMAxCD3 Prostate Cancer Expansion cohorts now enrolling; EGFRxCD28 Prese
Slide 18: Obesity combinations aim to improve quality of weight loss
Obesity combinations aim to improve quality of weight loss; exciting early data supporting potential unimolecular solutions GLP-1 based therapies, such as semaglutide (sema) and tirzepatide, are emerging as standards of care for weight loss; However, up to 40% of weight loss from these agents is due
Slide 19: Regeneron Genetic Medicines
Regeneron Genetic Medicines: harnessing the potential of multiple investigational approaches for treatment of genetic diseases Established clinical proof-of-principle across several diseases with novel, cutting-edge genetic medicine technologies siRNA CRISPR Gene Silencing Knockout and Insertion AAV
Slide 20: Regeneron restores hearing in a profoundly deaf child
Bringing solutions – and hope – to hearing loss: Regeneron restores hearing in a profoundly deaf child & shows improvement in second child Potentially one-time gene therapy for infants born with profound deafness due to biallelic OTOF mutations • DB-OTO is a surgically delivered AAV-based dual-vecto
Slide 21: Spotlight: first child dosed with DB-OTO can hear
Spotlight: first child dosed with DB-OTO can hear • First child was born completely deaf due to mutations in the otoferlin gene, and was dosed unilaterally with DB-OTO gene therapy at 10 months old • Within 4 weeks of receiving DB-OTO as part of the CHORD trial, the child responded to sound in the t
Slide 22: Regeneron-discovered, approved and investigational medicines
Regeneron-discovered, approved and investigational medicines across a diverse set of diseases Phase 1 Phase 2 Phase 3 Approved † REGN5459 (BCMAxCD3) REGN9933 (Factor XI) pozelimab + cemdisiran‡ ° REGN5837 (CD22xCD28) (anti-C5 + C5 siRNA) REGN7257 (IL-2Rγ) odronextamab (CD20xCD3) vidutolimod (TLR9) §
Slide 23: 2024 key upcoming milestones
2024 key upcoming milestones Solid Organ Oncology • Report potentially pivotal interim analysis of LIBTAYO in Adjuvant CSCC (2H) Ophthalmology • Report results from Phase 3 study of fianlimab + LIBTAYO in 1L metastatic melanoma (2025); initial data in 1L advanced NSCLC (2H) • EU decision for afliber
Slide 24: Continuing to deliver on capital allocation priorities
Continuing to deliver on capital allocation priorities to drive long-term growth Internal Business Investment Repurchase Development Shares in our world-class R&D capabilities to expand pipeline and maximize and capital expenditures to • Deploy excess cash to commercial opportunities opportunistical
Slide 25: Three responsibility focus areas
Three responsibility focus areas reflect our “doing well by doing good” ethos 1 2 3 Improve the lives of people Foster a culture of integrity Build sustainable Use the power of with serious diseases and excellence communities science to repeatedly • Pipeline innovation • Product quality and safety •
Slide 26: 2023 Highlights
2023 HIGHLIGHTS (>) 'MPROVING THE LIVES OF PEOPLE \ FOSTERING A CULTURE OF >) BUILDING SUSTAINABLE \Y WITH SERIOUS DISEASES INTEGRITY & EXCELLENCE COMMUNITIES fe) 9 9 ~2.3M ~35 88% 70 % a2, exomes sequenced since investigational medicines of colleagues said Regeneron colleague retention rate of coll
Slide 27: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations 26
Slide 28: Abbreviations and Definitions
Abbreviations and Definitions Abbreviation Definition Abbreviation Definition 1L First line HCC Hepatocellular carcinoma AAV Adeno-associated virus HNSCC Head and neck squamous cell carcinoma ALS Amyotrophic lateral sclerosis KM Kaplan-Meier curve APP Amyloid precursor protein LAG-3 Lymphocyte-activ
Regeneron Pharmaceuticals — Shareholder Meeting (June 2024) on 6ix